Dr. Barghian is the President and Chief Executive Officer of ARA – Avanti Rx Analytics Inc., located in Ontario, Canada where he leads a team of highly skilled scientist and regulatory professionals dedicated to conducting analytical quality control, R&D, QA, RA, extraction, and purification on cannabinoids.
Dr. Barghian leverages background in organic synthesis, analytical chemistry, terpene science, and long standing experience in pharmaceutical quality control, quality assurance and regulatory affairs.
Dr. Barghian is also researcher conducting clinical studies on effects of CBD and CBG on mammalian cancer in collaboration with University of Georgia, school of medicine, Georgia, USA. His earlier career as a pharmaceutical R&D and Quality Control leader included positions with Genpharm (now known as Mylan), Apotex, Ciba Vision (now known as Alcon), and Aventis Pasteur (now known as Sanofi Pasteur).
Dr. Barghian earned his M.Phil. and Ph.D. in organic synthesis and analytical Chemistry from University of Cardiff, Wales, United Kingdom, and completed his CRC (Cancer Research Campaign) Post-doctoral research at the Queen Mary Westfield College, University of London, England.
Dr. Barghian is the president of the International Pharmaceutical Academy (IPA) and lectures throughout the world on numerous GMP compliance, validation, and analytical testing related matters.
Mr. Ponomarev is a former Health Protection Branch (HPB) - Health Canada Senior GMP Drug Specialist/Compliance Investigator with over 20 years of service with the Health Canada.
After a 40-year career in the pharmaceutical industry Mr. Ponomarev is now a Senior Associate with Lachman Consultants, a world renowned compliance and regulatory affairs consulting firm based in USA and a senior board member of ARA – Avanti Rx Analytics Inc.
Prior to Lachman, Mr. Ponomarev held number of progressive senior positions where he delivered the strategic guidance and direction toward implementation of effective solutions for; quality systems, conducting pre-approval inspections, drug submissions, and commercialization.
In the past Mr. Ponomarev had held senior Quality and Compliance positions in multi-national pharmaceutical and biotech organizations such as; Aventis Pasture, Novartis Pharmaceuticals, Genpharm, and KGA Merck.
Additionally, he is highly skilled in remediation planning and implementation. Mr. Ponomarev’s expertise in quality systems design, enhancement, and implementation strengthens corporate total quality tenets to achieve company goals of compliance and profitability.